Advertisement
UK markets open in 2 hours 2 minutes

  • NIKKEI 225

    38,218.33
    -55.72 (-0.15%)
     

  • HANG SENG

    18,155.28
    +392.25 (+2.21%)
     

  • CRUDE OIL

    79.56
    +0.56 (+0.71%)
     

  • GOLD FUTURES

    2,328.20
    +17.20 (+0.74%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • Bitcoin GBP

    45,718.91
    -2,330.91 (-4.85%)
     

  • CMC Crypto 200

    1,261.86
    -77.20 (-5.77%)
     

  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     

  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     
Money:

Family finances

Who is the breadwinner in your family and does it matter?

Sherlock Bio to buy UK firm in quest for CRISPR-based handheld diagnostic tests

Reuters
·1-min read

(Reuters) - Privately-held Sherlock Biosciences said on Wednesday it has acquired UK-based Sense Biodetection to speed up the launch of handheld diagnostic tests that use the breakthrough CRISPR gene editing technology.

Sherlock raised $80 million nearly a year ago for development of diagnostics based on the CRISPR tool, which is designed to work like a pair of genetic scissors.

The company declined to comment on financial terms of the deal with Sense.

Sherlock was the first company to gain authorization for a CRISPR-based COVID-19 test in 2020.

The diagnostics company said the deal, which gives access to Sense's genetic testing platform Veros, would help accelerate the launch of handheld tests for a range of respiratory and sexual health diseases.

(Reporting by Mariam E Sunny in Bengaluru; Editing by Krishna Chandra Eluri)